Apr 22, 2023
Dr. Ali Siahpush, Pharmefex president and founder today announced that Klaus Beck, MD, Ph.D. will be joining Pharmefex as a Principal Consultant.
Klaus is a physician and scientist with 30 years of industry experience in R&D.
Over his successful career he has held roles with increasing leadership responsibility in the US, Japan and the Asia-Pacific Region as well as Europe, Middle East and Africa, working across the R&D commercialization spectrum, spanning from discovery, translational and clinical research to launch, medical affairs and maintenance, plus global business development and licensing. Klaus worked at Genentech, Amgen, Elan, AstraZeneca, Merck & Co and Organon & Co in local, regional and global roles. His most recent role was as Chief Medical Officer and SVP for Organon with global responsibility for Clinical Development and Pharmacovigilance as well as chair or co-chair for several R&D and corporate strategy committees. Klaus has extensive product commercialization experience, having supported the launches and maintenance of several products in both US and Europe.
Klaus holds MD/PhD degrees (PhD in pharmacology) from University of Heidelberg, and a PhD (Neuroscience) from USC, Los Angeles.
The addition of Klaus adds significant capabilities to Pharmefex as we strive to serve our clients across the R&D spectrum and world wide.